Can You Take Zolpidem with Clonazepam?

Severity assessment

Major. The concurrent use of clonazepam and zolpidem significantly increases the risk of severe central nervous system (CNS) and respiratory depression, potentially leading to excessive sedation, impaired consciousness, respiratory arrest, and death.

Mechanism (plain English)

Both clonazepam, a benzodiazepine, and zolpidem, a Z-drug, work by enhancing the activity of gamma-aminobutyric acid (GABA) in the brain. GABA is a natural chemical that reduces brain activity, leading to calming and sedative effects. When taken together, these medications have an additive effect, meaning their individual sedative and respiratory depressant actions are combined and amplified. This can result in profound drowsiness, slowed breathing, and impaired mental and physical functions.

Evidence level

Regulator-flagged. Major regulatory bodies, including the FDA, MHRA, and TGA, have issued warnings and strengthened advisories concerning the risks associated with benzodiazepines and Z-drugs, particularly when used with other CNS depressants.

Top regulator advisories (cite verbatim or close paraphrase)

• TGA (Australia): The TGA imposed a boxed warning for zolpidem, advising that "Zolpidem may be associated with potentially dangerous complex sleep-related behaviours which may include sleep walking, sleep driving and other bizarre behaviours. Zolpidem is not to be taken with alcohol. Caution is needed with other CNS depressant drugs. Limit use to four weeks maximum under close medical supervision." [1]
• MHRA / NICE (UK): The MHRA strengthened warnings on benzodiazepines and Z-drugs, stating that these medicines "May cause addiction, dependence, and withdrawal reactions." They also recommend against using these medicines with opioids or alcohol. [2]
• FDA / CDC (US): The FDA requires a Boxed Warning for all benzodiazepine medicines to describe the risks of abuse, misuse, addiction, physical dependence, and withdrawal reactions. [3] Additionally, the FDA has issued warnings regarding next-morning impairment with zolpidem and required lower recommended doses for certain zolpidem products. [4]
• EMA (Europe): No specific pair-specific public advisory found for clonazepam and zolpidem. However, the EMA has general guidance on the safe use of benzodiazepines and Z-drugs, emphasizing risks of dependence and withdrawal.

Clinical risk factors that elevate the danger

Patient factors: Elderly or debilitated patients, individuals with pre-existing respiratory conditions (e.g., sleep apnea, COPD), those with a history of substance abuse (alcohol or other drugs), and patients with liver impairment are at higher risk. Individuals with psychiatric conditions may also be more vulnerable to adverse effects. Medicine-use factors: Higher doses of either medication, concurrent use of other CNS depressants (e.g., opioids, alcohol, other sedatives), rapid dose escalation, and prolonged use increase the risk of severe adverse outcomes.

What a patient should be told

• Risk: Taking clonazepam and zolpidem together can make you very drowsy, dizzy, and can dangerously slow your breathing. This combination significantly increases your risk of falls, accidents, and serious breathing problems, especially if you also drink alcohol or take other sedating medicines.
• Do not stop suddenly: Never stop taking these medications suddenly without talking to your doctor or pharmacist first, as this can cause severe withdrawal symptoms.
• Warning signs: Be aware of warning signs like extreme drowsiness, confusion, difficulty waking up, very slow or shallow breathing, or unusual behaviors (like sleepwalking or sleep-driving). If these occur, seek immediate medical attention.
• Safer alternatives: Discuss with your doctor or pharmacist if there are safer alternative treatments for your conditions that do not carry such high risks when combined.
• Urgent care: If you or someone you know experiences severe difficulty breathing, unresponsiveness, or extreme confusion after taking these medications, call emergency services immediately.

Top 3 sources (with full citation)

1. Therapeutic Goods Administration. Zolpidem ('Stilnox'). Published 21 February 2008. Available at: https://www.tga.gov.au/safety/recalls-and-other-market-actions/market-actions/zolpidem-stilnox
2. Medicines and Healthcare products Regulatory Agency. MHRA strengthening dependency and addiction warnings on medicines used to treat pain, anxiety, and insomnia. Published 8 January 2026. Available at: https://www.gov.uk/government/news/mhra-strengthening-dependency-and-addiction-warnings-on-medicines-used-to-treat-pain-anxiety-and-insomnia
3. U.S. Food and Drug Administration. Benzodiazepine Drug Class: Drug Safety Communication - Boxed Warning Updated to Improve Safe Use. Published 23 September 2020. Available at: https://www.fda.gov/safety/medical-product-safety-information/benzodiazepine-drug-class-drug-safety-communication-boxed-warning-updated-improve-safe-use
4. U.S. Food and Drug Administration. Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem. Published 10 January 2013. Available at: https://www.fda.gov/files/drugs/published/Drug-Safety-Communication--Risk-of-next-morning-impairment-after-use-of-insomnia-drugs--FDA-requires-lower-recommended-doses-for-certain-drugs-containing-zolpidem-%28Ambien--Ambien-CR--Edluar--and-Zolpimist%29.pdf

Notes for the reviewing pharmacist

The interaction between clonazepam and zolpidem is well-established due to their shared mechanism of action on GABA receptors, leading to additive CNS depression. While both are individually associated with risks of dependence and withdrawal, their co-administration significantly escalates these concerns, as highlighted by multiple regulatory bodies. There is no contested evidence regarding the existence of this interaction; rather, the focus is on appropriate prescribing practices, patient education, and risk mitigation. Common misconceptions might include underestimating the additive effects, especially at lower doses, or assuming that Z-drugs are inherently safer than benzodiazepines in combination. Pharmacists should emphasize the importance of avoiding concomitant use, counseling on non-pharmacological alternatives for insomnia and anxiety, and ensuring gradual tapering if discontinuation is necessary. Population-specific concerns include heightened sensitivity in the elderly, increased risk of respiratory depression in patients with pulmonary compromise, and potential for abuse in individuals with a history of substance use disorder.

Source metadata JSON

{
  "pair": "clonazepam + zolpidem",
  "severity": "Major",
  "evidence_level": "Regulator-flagged",
  "source_urls": "https://www.tga.gov.au/safety/recalls-and-other-market-actions/market-actions/zolpidem-stilnox; https://www.gov.uk/government/news/mhra-strengthening-dependency-and-addiction-warnings-on-medicines-used-to-treat-pain-anxiety-and-insomnia; https://www.fda.gov/safety/medical-product-safety-information/benzodiazepine-drug-class-drug-safety-communication-boxed-warning-updated-improve-safe-use; https://www.fda.gov/files/drugs/published/Drug-Safety-Communication--Risk-of-next-morning-impairment-after-use-of-insomnia-drugs--FDA-requires-lower-recommended-doses-for-certain-drugs-containing-zolpidem-%28Ambien--Ambien-CR--Edluar--and-Zolpimist%29.pdf"
}